Title: Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models Date: January 6, 2022 Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery Virtual…
Read More
Background Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant…
Abstract: Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology depends on accurate characterization of tumor mutations and subsequent therapy selection….
The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for…
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Despite an increasing demand for precision medicine enabled by NGS measurement of actionable mutations in circulating tumor DNA (ctDNA) specimens, the ability to reliably measure and report low-frequency mutations using…
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021 Poster #: P252, Presenter: Brett Hall, Ph.D., Immuneering Chief Scientific Officer
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021 Poster #: P240 Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021 Poster #: P254 Presenter: Sarah Kolitz, Ph.D., Immuneering Vice President, Translational Medicine
Reproducibility is essential to open science, as there is limited relevance for findings that can not be reproduced by independent research groups, regardless of its validity. It is therefore crucial…
The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics….
